CONFIDENTIAL — APPROVED FOR PUBLIC RELEASE · BUREAU FILE COPY RECORDS CURRENT AS OF 29 MAY 2026 · DISTRIBUTION: UNRESTRICTED
VendorInvestigate Independent Testing Bureau · Public Records Division
DOCKET YEAR 2026 · VOL. II
13,421 SAMPLES ON FILE
No fee · No favor
Compound Evidence File
#EC-2026-0626

Tamoxifen (Nolvadex) Raw

Filed under Raw Materials. The bureau holds 61 laboratory returns for this compound from 18 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.

Cross-Index

Subjects Shipping This Compound

18 SUBJECTS
SubjectGradeSamplesMeanMinMaxFirst seenLast seen
HomopeptideCASE #VI-2026-0760A610.09.910.024 May 202624 May 2026
Trusted PeptideCASE #VI-2026-0499X110.010.010.07 May 20257 May 2025
Tianjin Finder Chemical TFCCASE #VI-2026-0693A49.99.910.014 Nov 202516 Apr 2026
Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594A29.38.710.023 May 202623 May 2026
Shanghai Sigma Audley SSACASE #VI-2026-0486A89.07.99.725 May 202625 May 2026
Qingdao Sigma Chemical QSCCASE #VI-2026-0538A88.57.39.624 May 202624 May 2026
Nantong Guangyuan Chemical GYCCASE #VI-2026-0284A88.56.410.021 May 202621 May 2026
Glbiochem (Shanghai)CASE #VI-2026-0704A88.26.810.024 May 202624 May 2026
Heman Peptide HMCASE #VI-2026-0089X18.18.18.111 Jun 202511 Jun 2025
Precision Peptide CoCASE #VI-2026-0559X17.97.97.92 Jul 20252 Jul 2025
Verified PeptidesCASE #VI-2026-0407X27.86.39.325 Apr 202517 May 2026
Hebei Rimao TechnologyCASE #VI-2026-0529X37.66.98.22 Jul 202521 May 2026
ScienceCASE #VI-2026-0636X17.47.47.428 Mar 202528 Mar 2025
Yongkang Nuoao Trading CoCASE #VI-2026-0646X17.47.47.42 Apr 20252 Apr 2025
LN PeptidesCASE #VI-2026-0781X26.25.47.028 Mar 202525 May 2026
Quenna PMQCASE #VI-2026-0415X15.65.65.625 Apr 202525 Apr 2025
TydesCASE #VI-2026-0493X45.04.25.52 Jul 202526 Jan 2026
Shanghai OuDaXin New Material Technology CenterCASE #VI-2026-0498X14.34.34.320 Jun 202520 Jun 2025

Open any subject to view the batch-level evidence for Tamoxifen (Nolvadex) Raw alone.